Русский
Clinical-functional and molecular-genetic peculiarities of patients with chronic heart failure
DOI: https://dx.doi.org/10.18565/therapy.2024.4.41-49
Zimina Yu.D., Gerasimenko O.N., Voronina E.N., Tolmacheva A.A.
1) Novosibirsk State Medical University of the Ministry of Healthcare of Russia; 2) Institute of Chemical Biology and Fundamental Medicine of the Siberian branch of the Russian Academy of Sciences, Novosibirsk
The aim: to evaluate clinical, functional and molecular genetic characteristics of patients with CHF.
Material and methods. The study included 157 patients (average age 68.9 ± 9.5 years) with diagnosed CHF, who underwent laboratory, instrumental and molecular genetic studies (polymorphisms rs632793 of NPPB gene and rs5065 of NPPA gene). The participants were divided into two groups: the 1st group included male pesons (n = 79), the 2nd group included female persons (n = 78). Next, among the study persons (n = 157), a subgroup of patients with the results of molecular genetic study was identified in the quantity of 68 persons (36 males and 32 females).
Results and conclusion. Among all studied patients (n = 157), stage IIa CHF (52.3%, n = 82), III functional class of the disease (63%, n = 99), CHF with preserved ejection fraction (52.8%, n = 83) were most common. When assessing comorbid pathologies, the leading position was occupied by hypertension (96.8%, n = 152). In the group of male patients, persons of working age were more common (p < 0.001). When analyzing comorbid conditions, a significantly higher frequency of permanent atrial fibrillation (AF) was revealed in the group of men (p = 0.04). According to the results of laboratory and instrumental examination methods, no significant differences were identified. A correlation was found between the rs632793 polymorphism of NPPB gene and AF in CHF in female patients (odds ratio 6.600; 95% confidence interval: 1.229–35.439; p = 0.02). Obtained data could be used for personalized assessment of the risk of AF developing in case of CHF.
Literature
1. Резник Е.В., Ушакова Н.А., Ершов Н.С. с соавт. Гендерные и возрастные особенности больных с хронической сердечной недостаточностью в реальной клинической практике. РМЖ. Медицинское обозрение. 2023; 7(1): 13–21. (Reznik E.V., Ushakova N.A., Ershov N.S. et al. Gender and age characteristics of patients with chronic heart failure in real clinical practice. Russkiy meditsisnkiy zhurnal. Meditsinskoye obozreniye = Russian Medical Journal. Medical Review. 2023; 7(1): 13–21 (In Russ.)). https://doi.org/10.32364/2587-6821-2023-7-1-13-21. EDN: ERSYEA. 2. Поляков Д.С., Фомин И.В., Вайсберг А.Р. ЭПОХА-Д-ХСН: гендерные различия в прогнозе жизни больных ХСН при острой декомпенсации сердечной недостаточности (часть 2). Кардиология. 2019; 59(S4): 33–43. (Polyakov D.S., Fomin I.V., Weisberg A.R. EPOKHA-D-CHF: gender differences in the prognosis of life of patients with CHF with acute decompensated heart failure (part 2). Cardiology. 2019; 59(S4): 33–43 (In Russ.)). https://doi.org/10.18087/cardio.2654. EDN: JROYOF. 3. Andersson C., Nayor M., Tsao C.W. et al. Framingham Heart Study: JACC Focus Seminar, 1/8. J Am Coll Cardiol. 2021; 77(21): 2680–92. https://doi.org/10.1016/j.jacc.2021.01.059. PMID: 34045026. 4. Матюкевич М.Ч., Снежицкий В.А. Система натрийуретических пептидов при хронической сердечной недостаточности: фокус на практические аспекты терапии через результаты фундаментальных исследований. Медицинские новости. 2021; (10): 16–21. (Matyukevich M.Ch., Snezhitskiy V.A. Natriuretic peptides in chronic heart failure: Practical aspects of therapy through the results of basic research. Meditsinskiye novosti = Medical News. 2021; (10): 16–21 (In Russ.)). EDN: MPVMCS. 5. Богданов А.Р., Дербенева С.А., Черняк О.О. с соавт. Генетические предикторы хронической сердечной недостаточности у больных ожирением. Ожирение и метаболизм. 2019; 16(1): 39–46. (Bogdanov A.R., Derbeneva S.A., Chernyak O.O. et al. Genetic predictors of chronic heart failure in obese patients. Ozhirenie i metabolism = Obesity and Metabolism. 2019; 16(1): 39–46 (In Russ.)). https://doi.org/10.14341/omet9667. EDN: JEEQAT. 6. Newton-Cheh C., Larson M., Vasan R. et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009; 41(3): 348–53. https://doi.org/10.1038/ng.328. PMID: 19219041. PMCID: PMC2664511. 7. Зимина Ю.Д., Горбунова А.М., Толмачева А.А. с соавт. Современные генетические маркеры хронической сердечной недостаточности. Атеросклероз. 2023; 19(2): 140–144. (Zimina Yu.D., Gorbunova A.M., Tolmacheva A.A. et al. Modern genetic markers of chronic heart failure. Ateroskleroz = Atherosclerosis. 2023; 19(2): 140–144 (In Russ.)). https://doi.org/10.52727/2078-256X-2023-19-2-140-144. EDN: GJSKHJ. 8. Yang Y., Zmuda J.M., Wojczynski M.K. et al. Genetic association analysis of the cardiovascular biomarker: N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP). PLoS One. 2021; 16(3): e0248726. https://doi.org/10.1371/journal.pone.0248726. PMID: 33720941. PMCID: PMC7959346. 9. Xhaard C., Rouget R., Vodovar N. et al. Impact of natriuretic peptide polymorphisms on diastolic and metabolic function in a populational cohort: Insights from the STANISLAS cohort. ESC Heart Fail. 2022; 9(1): 729–39. https://doi.org/10.1002/ehf2.13674. PMID: 34734498. PMCID: PMC8788028. 10. Клинические рекомендации. Хроническая сердечная недостаточность. Российское кардиологическое общество, автономная некоммерческая организация «Национальное общество по изучению сердечной недостаточности и заболеваний миокарда», общероссийская общественная организация «Общество специалистов по сердечной недостаточности». Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 156. Доступ: http://cr.rosminzdrav.ru/schema/156_1 (дата обращения – 01.05.2024). (Clinical guidelines. Chronic heart failure. Russian Society of Cardiology, National Society for the Study of Heart Failure and Myocardial Diseases, Society of Heart Failure Specialists. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2020. ID: 156. URL: http://cr.rosminzdrav.ru/schema/156_1 (date of access – 01.05.2024) (In Russ.)). 11. McDonagh T.A., Metra M., Adamo M. с соавт. 2021 Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности. Российский кардиологический журнал. 2023; 28(1): 117–224. (McDonagh T.A., Metra M., Adamo M. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2023; 28(1): 117–224 (In Russ.)). https://doi.org/10.15829/1560-4071-2023-5168. EDN: SJMIKK.
About the Autors
Yulia D. Zimina, MD, postgraduate student of the Department of faculty therapy named after professor Zalessky G.D. of the Faculty of general medicine, Novosibirsk State Medical University of the Ministry of Healthcare of Russia. Address: 630091, Novosibirsk, 52 Krasny Avenue.
E-mail: yulya_tx@mail.ru
ORCID: https://orcid.org/0000-0001-9027-6884
Oksana N. Gerasimenko, MD, Dr. Sci. (Medicine), professor, head of the Department of faculty therapy named after professor Zalessky G.D. of the Faculty of general medicine, Novosibirsk State Medical University of the Ministry of Healthcare of Russia. Address: 630091, Novosibirsk, 52 Krasny Avenue.
E-mail: profgerasimenko@inbox.ru
ORCID: https://orcid.org/0000-0002-9742-0479
Elena N. Voronina, MD, PhD (Biology), head of the group, senior researcher at the molecular genetics group of Institute of Chemical Biology and Fundamental Medicine of the Siberian branch of the Russian Academy of Sciences. Address: 630090, Novosibirsk, 8 Academika Lavrentieva Avenue.
E-mail: voronina_l@mail.ru
Anastasia A. Tolmacheva, MD, PhD (Medicine), assistant at the Department of faculty therapy named after professor Zalessky G.D. of the Faculty of general medicine, Novosibirsk State Medical University of the Ministry of Healthcare of Russia. Address: 630091, Novosibirsk, 52 Krasny Avenue.
E-mail: tolmacheva_nastena@mail.ru
ORCID: https://orcid.org/0000-0003-1687-4100
Similar Articles
